Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
126 hedge funds and large institutions have $574M invested in Keryx Biopharmaceuticals Inc in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 48 increasing their positions, 24 reducing their positions, and 11 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
100% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 24
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
36% more capital invested
Capital invested by funds: $424M → $574M (+$150M)
33% more call options, than puts
Call options by funds: $6.15M | Put options by funds: $4.63M
9.33% more ownership
Funds ownership: 63.88% → 73.22% (+9.3%)
6% more funds holding
Funds holding: 119 → 126 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$43.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.08M |
| 3 |
Millennium Management
New York
|
+$3.63M |
| 4 |
MPAM
Monarch Partners Asset Management
Boston,
Massachusetts
|
+$2.64M |
| 5 |
CEP
Chicago Equity Partners
Chicago,
Illinois
|
+$2.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.92M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.2M |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$907K |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$875K |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$513K |
KERX Hedge Fund Activity: Q2 2017 in Review
126 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q2 2017, worth a combined $574M — up 36% from $424M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new KERX positions and 11 closed out — a net gain of 8 holders — while 48 added to existing stakes and 24 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $43.8M. The largest seller was Ameriprise, cutting an estimated $2.92M.
- 126 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q2 2017, up from 119 in Q1 2017.
- Funds reported $574M of Keryx Biopharmaceuticals Inc stock for Q2 2017, up 36% quarter-over-quarter.
- 19 funds opened new Keryx Biopharmaceuticals Inc positions in Q2 2017 and 11 closed out, a net change of +8 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q2 2017 was Consonance Capital Management, an estimated $43.8M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q2 2017 was Ameriprise, an estimated $2.92M sold.
Based on aggregated 13F filings for Q2 2017.